Press Release

A clinical evaluation of BioEcolians® (α-gluco-oligosaccharide) was performed on a group of sub-jects presenting moderate irritable bowel syndrome with constipation symptom (IBS-C). The study was conducted in double blind vs. placebo on two groups of 25 subjects each after a period of 28 days. The active group was given a daily dose of 2g.The results show a reduction of the disorders from the 7th day on abdominal bloating and from the 14th on pain and discomfort. On average, a 50% decrease of the symptoms is observed after 28 days. Over the same period, the people saw also their general transit significantly improved. The clinical study highlighted BioEcolians® key effects:

•Increases gut Lactobacilli and Bifidobacteria

•Reduces the sensation of digestive discomfort (bloating, pain)

•Improves bowel movement

•Promotes short chain fatty acids producing bacteria

•Stimulates ß-defensins production (patent pending)

The clinical study demonstrated the efficacy at a low active dosage: 2g daily for rapid effects, thus suggesting for 1g daily as a maintenance dose.BioEcolians® is obtained by an enzymatic synthesis process, perfectly controlled, which ensures optimal reproducibility of its characteristics, in a ISO 9001 & 14001, OHSAS 18001 and GMP certi-fied manufacturing site. BioEcolians® is GRAS certified.Solabia specializes in manufacturing proprietary quality ingredients to the food, dietary supple-ment, and pharmaceutical industries. With more than 40 years of experience, Solabia has deve-loped an expertise in the creation and production of innovative ingredients that meet the increa-sing consumer demand for natural products that promote health and wellness.

Contact Solabia at: [email protected] - www.solabia.com